Samantha Kendrick

Federal Grant PI

Associate Professor

UAMS

Last publication 2026 Last refreshed 2026-05-22

faculty

Biochemistry & Molecular Biology, College of Medicine

skendrick@uams.edu

16 h-index 104 pubs 1,789 cited

Research Areas

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Samantha Kendrick's research focuses on understanding the molecular mechanisms underlying cancer, with a particular emphasis on lymphoma and other oncogenic pathways. She investigates novel therapeutic targets, including G-quadruplex DNA structures within oncogene promoters, such as CARD11 and MYD88. Her work explores the potential of targeting these structures with specific compounds, like naptho(2,1-b)furan-1-ethanol,2-nitro-, to inhibit cancer cell growth.

Kendrick also examines the role of specific genes and cellular processes in cancer development and progression. This includes investigating bifunctional inhibitors targeting NEK2, a regulator of oncogenic pathways in lymphoma, and exploring oncolytic strategies using inhibitors against virus-associated lymphomas. Her research has also delved into the effects of antiviral drugs, such as remdesivir, on oncogenic herpesvirus reactivation and identified natural compounds like tubercidin and lycorine HCl as potential therapeutic agents for small-cell lung cancer.

Her scholarship metrics include an h-index of 16 with 102 total publications and 1,773 total citations. Kendrick has received federal funding for two awards totaling $1,220,115, including a PI role on the NIH/NCI Partnership in Cancer Research (PCAR) grant and a Co-PI role on an NSF grant studying G-quadruplex DNA replication. She actively collaborates with several researchers at the University of Arkansas for Medical Sciences, including Ying-Zhi Xu, Mason McCrury, Kennith Swafford, and Syed Hassan Mehdi, with whom she shares a significant number of publications.

Metrics

h-index: 16
Publications: 104
Citations: 1,789

Selected Publications

G-quadruplex and i-motif DNA structures form in the promoter of the key innate immune adaptor MYD88 (2025)

5 citations DOI OpenAlex
Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma (2023)

13 citations DOI OpenAlex
Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas (2023)

13 citations DOI OpenAlex
Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group (2022)

6 citations DOI OpenAlex
Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target (2022)

15 citations DOI OpenAlex
The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways (2022)

21 citations DOI OpenAlex
Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models (2021)

DOI OpenAlex
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma (2021)

35 citations DOI OpenAlex
Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome (2021)

DOI OpenAlex
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)

4 citations DOI OpenAlex
The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure (2021)

88 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 2 $1,220,115 total

NIH/National Cancer Institute Contact PI Sep 2020 - Apr 2026

Partnership in Cancer Research (PCAR)

National Cancer Institute $120,115 R25

NSF Co-PI May 2024 - Apr 2028

Replication of G-quadruplex DNA by translesion polymerases

Cross-BIO Activities, Genetic Mechanisms $1,100,000

Grants & Funding

Targeting unique DNA structures to repress oncogenic signaling in lymphoma DoD Principal Investigator
No FP attached UAMS ACHRI Flow Through Principal Investigator
Targeting unique DNA structures to repress oncogenic signaling in lymphoma US Department of Defense Principal Investigator
Targeting unique DNA structures to repress oncogenic signaling in lymphoma US Department of Defense Principal Investigator
Impact of DNA topology on facilitating mutational events in lymphoma American Cancer Society, Inc. Principal Investigator
Impact of DNA topology on facilitating mutational events in lymphoma American Cancer Society, Inc. Principal Investigator
Seeds of Science Pilot award UAMS Internal Research Awards Principal Investigator
Targeting oncogenic regulation through unique DNA structures in lymphoma NIH/NIGMS Principal Investigator